Leveraging AI, analytics and cloud technologies, MedQIA’s technology platform offers state-of-the-art imaging services for clinical trials. This technology is used to support the pharmaceutical, biotechnology and medical device industries.
MedQIA was approached by two buyers and was not sure how to react to the offers on the table. With GHJ’s advice, the client decided to more broadly shop the business. After a thorough search, MedQIA found a fit and a merger of entities took place between MedQIA and WorldCare Clinical, the world’s largest independent contract research organization dedicated to imaging in clinical trials.
The resulting entity, Voiant, is an industry-leading AI-based clinical trial imaging platform that provides high-speed delivery of quality clinical endpoint data to biopharmaceutical organizations.
GHJ’s Growth Planning and Strategic Advisory Team helped the owners engage investment banker Cascadia Capital and acted as a sounding board for MedQIA throughout the merger process.